Skip to main content Accessibility help
×
×
Home

Long-term safety and tolerability of iloperidone: results from a 25-week, open-label extension trial

  • Andrew J. Cutler (a1) (a2), Amir H. Kalali (a3) (a4), Greg W. Mattingly (a5) (a6), Jelena Kunovac (a7) (a8) and Xiangyi Meng (a9)...

Abstract

Introduction/Objective

Long-term use of the atypical antipsychotic iloperidone has not been investigated at doses above 16 mg/d. This article describes safety and tolerability results from the 25-week open-label extension of a 4-week placebo- and ziprasidone-controlled clinical trial of iloperidone.

Methods

Patients received a dose of 24 mg/d (given as 12 mg twice daily; mean dose = 21.6 mg) that could be reduced to 12 mg/d (given once daily at bedtime) any time after day 35 at the investigator's discretion.

Results

A total of 72/173 patients (41.6%) completed the open-label extension. Treatment-emergent adverse events (TEAEs), most mild to moderate in severity, included headache (13.9%), weight increase (9.2%), dizziness (6.9%), nausea (6.4%), sedation (6.4%), and insomnia (5.2%). The only notable dose-related TEAEs were increased weight and headache. Levels of serum glucose, lipids, and prolactin were essentially unchanged or decreased during treatment. In general, akathisia and extrapyramidal symptoms (EPS) improved or were unchanged during treatment. There was no signal of worsening of efficacy based on changes from baseline in the Positive and Negative Syndrome Scale-Total.

Discussion/Conclusion

This study further supports the long-term safety and tolerability of iloperidone for the treatment of schizophrenia, including iloperidone's favorable effect on metabolic laboratory parameters and low propensity to cause akathisia or EPS.

Copyright

Corresponding author

*Address for correspondence: Andrew J. Cutler, MD, Courtesy Assistant Professor, Department of Psychiatry, University of Florida, 8043 Cooper Creek Blvd., Suite 107, Bradenton, FL 34201, USA. (Email acutler@flcrc.com)

Footnotes

Hide All

This clinical study was funded by Vanda Pharmaceuticals. Assistance with manuscript preparation was provided by Oxford PharmaGenesis, Inc., and this assistance was funded by Novartis Pharmaceuticals Corporation. The authors would also like to acknowledge project management support to Novartis provided by Arlene Kaufman of Research Pharmaceuticals, Inc. The authors wish to acknowledge the significant contributions of Dr. Paolo Baroldi and Rebecca Lannan, formerly of Vanda Pharmaceuticals, and of Dr. Curt Wolfgang and Jennifer Hamilton of Vanda Pharmaceuticals.

Footnotes

References

Hide All
1.McEvoy, JP. The costs of schizophrenia. J Clin Psychiatry. 2007; 68(Suppl 14): 47.
2.Rössler, W, Salize, HJ, van Os, J, etal. Size of burden of schizophrenia and psychotic disorders. Eur Neuropsychopharmacol. 2005; 15: 399409.
3.Potkin, SG, Litman, RE, Torres, R, Wolfgang, CD. Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies. J Clin Psychopharmacol. 2008; 28(2 Suppl 1): S4S11.
4.Cutler, AJ, Kalali, AH, Weiden, PJ, etal. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. J Clin Psychopharmacol. 2008; 28(2 Suppl 1): S20S28.
5.Weiden, PJ, Cutler, AJ, Polymeropoulos, MH, etal. Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials. J Clin Psychopharmacol. 2008; 28(2 Suppl 1): S12S19.
6.Kane, JM, Lauriello, J, Laska, E, etal. Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia. J Clin Psychopharmacol. 2008; 28(2 Suppl 1): S29S35.
7.Chouinard, G, Margolese, HC. Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophr Res. 2005; 76(2–3): 247265.
8.Barnes, TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989; 154: 672676.
9.Breier, A, Berg, PH, Thakore, JH, etal. Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia. Am J Psychiatry. 2005; 162: 18791887.
10.Kane, JM, Osuntokun, O, Kryzhanovskaya, LA, etal. A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. J Clin Psychiatry. 2009; 70: 572581.
11.Simpson, GM, Weiden, P, Pigott, T, etal. Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia. Am J Psychiatry. 2005; 162: 15351538.
12.Kinon, BJ, Lipkovich, I, Edwards, SB, etal. A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms. J Clin Psychopharmacol. 2006; 26(2): 157162.
13.Kiraly, B, Gunning, K, Leiser, J. Primary care issues in patients with mental illness. Am Fam Physician. 2008; 78(3): 355362.
14.McEvoy, JP, Lieberman, JA, Perkins, DO, etal. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry. 2007; 164: 10501060.
15.Reynolds, GP, Zhang, Z, Zhang, X. Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain. Am J Psychiatry. 2003; 160: 677679.
16.Ellingrod, VL, Perry, PJ, Ringold, JC, etal. Weight gain associated with the -759C/T polymorphism of the 5HT2C receptor and olanzapine. Am J Med Genet B Neuropsychiatr Genet. 2005; 134B: 7678.
17.Thompson, A, Lavedan, C, Volpi, S. Absence of weight gain association with the HTR2C -759C/T polymorphism in patients with schizophrenia treated with iloperidone. Psychiatry Res. 2010; 175: 271273.
18.Torre, DL, Falorni, A. Pharmacological causes of hyperprolactinemia. Ther Clin Risk Manag. 2007; 3: 929951.
19.Weiden, PJ. Discontinuing and switching antipsychotic medications: understanding the CATIE schizophrenia trial. J Clin Psychiatry. 2007; 68(Suppl 1): 1219.
20.Lieberman, JA, Stroup, TS, McEvoy, JP, etal. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005; 353: 12091223.
21.Weiden, PJ. EPS profiles: the atypical antipsychotics are not all the same. J Psychiatr Pract. 2007; 13: 1324.
22.Arato, M, O'Connor, R, Meltzer, HY. A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. Int Clin Psychopharmacol. 2002; 17: 207215.
23.Keks, NA, Ingham, M, Khan, A, etal. Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder. Randomised, controlled, open-label study. Br J Psychiatr. 2007; 191: 131139.
24.Fleischhacker, WW, McQuade, RD, Marcus, RN, etal. A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia. Biol Psychiatry. 2009; 65: 510517.
25.Samalin, L, Garnier, M, Llorca, P-M. Clinical potential of lurasidone in the management of schizophrenia. Ther Clin Risk Manag. 2011; 7: 239250.
26.Glassman, AH, Bigger, JT Jr. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry. 2001; 158(11): 17741782.
27.Strom, BL, Eng, SM, Faich, G, etal. Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: the Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC). Am J Psychiatry. 2011; 168: 193201.
28.U.S. Department of Health and Human Services, Food and Drug Administration. Guidance for industry: QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. October 2005. Available at: www.fda.gov/downloads/RegulatoryInformation/ucm129357.pdf. Accessed December 5, 2012.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

CNS Spectrums
  • ISSN: 1092-8529
  • EISSN: 2165-6509
  • URL: /core/journals/cns-spectrums
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed